Akeso's Penpulimab Monoclonal Antibody Submitted BLA in the United States
Akeso's Penpulimab Monoclonal Antibody Submitted BLA in the United States First Chinese PD-1 drug being BLA reviewed by the FDA under RTOR News provided by Share this article Share this article HONG KONG, May 24, 2021 /PRNewswire/ -- On May 24, 2021, Akeso, Inc. (HKEx: 9926.HK) announced that Penpulimab (research and development code: AK105), an PD-1 monoclonal antibody drug co-developed by the Company with Sino Biopharmaceutical Limited (HKEx: 1177.HK), has submitted a Biologics License Application ("BLA") to the Food and Drug Administration of the United States ("FDA") for third-line treatm...
Source: prnewswire.com
